Report

  1. Home
  2. Discounted reports

Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drugs [Endothelin Receptor Antagonists (ERAs), Prostacyclin and Prostacyclin Analogs, sGC Stimulators, and pde-5 Dipsticks], Type (Branded and Generics), Route of Administration (Oral, Intravenous/Subcutaneous, and Inhalational), and Distribution Channel (Hospital Pharmacies and Clinics, Online Pharmacies, and Retail Pharmacies)

Market Report I 2023-01-02 I 174 Pages I The Insight Partners
Discounted by 30% to 2024-06-30

The pulmonary arterial hypertension market is expected to grow from US$ 7,369.89 million in 2021 to US$ 10,889.08 million by 2028; it is estimated to grow at a CAGR of 5.8% from 2022 to 2028. The market growth is attributed to the growing incidence of pulmonary arterial hypertension and the rising approvals of pulmonary arterial hypertension drugs. However, the side effects of drugs used to treat pulmonary arterial hypertension hamper the market growth.

Pulmonary arterial hypertension (PAH) is a rare, progressive disorder caused due to high blood pressure (hypertension) in the arteries of the lungs. The increased pressure in the vessels may be caused by an obstruction in the small arteries in the lung for various reasons. The exact cause of PAH is unknown and although treatable; there is no permanent cure for the disease. PAH usually affects women between the age of 30-60 years..

Patent expiry permits generic drugs to penetrate the pulmonary arterial hypertension market and diversify product offerings. Over the next seven-eight years till 2030, the patented products are expected to go off-patent. This would provide an enormous opportunity for generic formulation companies in the coming years. AMBRISENTAN + TADALAFIL drug by Gilead Sciences, Inc. is used to treat PAH, and its patent will be expired by December 11, 2027. Many pharma companies are already working to develop the generic version of patented products, finds Care Ratings. After patent expiration, generic versions of drugs can become available. While consumers benefit from low prices, losing patent protection can expose pharmaceutical companies to growing competition. Thus, patent expiration is expected to open an opportunity for generic drug manufacturers to enter a new market during the forecast period.

Moreover, over the past 20 years, the arrival of 14 FDA-approved therapies for treating PAH is seen as a major feat considering that this disease affects a small population. The key to success in developing PAH therapies has been the immense advances in understanding the genetic and molecular mechanisms that drive the pathogenesis of the disease. With the growing awareness, the treatment strategies will continue to evolve and diversify from the current paradigm focused on vasoconstriction. Clinical trials are exploring the clinical efficacy of novel delivery devices and their utility in other forms of pulmonary hypertension and combination therapies. This will be the standard for clinical trials in the future.

Route of Administration-Based Insights

Based on route of administration, the pulmonary arterial hypertension market is segmented into oral, intravenous/subcutaneous, and inhalational. The oral segment held the largest pulmonary arterial hypertension market share in 2021 and is anticipated to register the highest CAGR during the forecast period. Orally administered agents used for the treatment of symptomatic, moderate-to-severe PAH include sildenafil and the endothelin (ET) receptor antagonists (ERAs), bosentan and sitaxentan (sitaxsentan), and abrisentan oral ET(A) receptor-selective ERA, with higher ET receptor affinity than bosentan. Moreover, new oral drugs for treating PAH include macitentan, riociguat, and treprostinil. Ambrisentan is an endothelin receptor antagonist indicated for treating PAH; WHO Group 1 and delay clinical worsening. In combination with tadalafil, ambrisentan is indicated to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability..

The pulmonary arterial hypertension market in North America held the largest share in the forecast period. The market growth in the region is attributed to the high prevalence of pulmonary arterial hypertension and initiatives by the government and manufacturers. The US pulmonary arterial hypertension market holds a significant share of the regional market. The prevalence of PAH in the US is much higher, although it is a rare disease. According to the American Lung Association, PAH is a rare and progressive disorder that accounts for about 500-1,000 new cases being diagnosed each year in the US. Additionally, as per the same source, ~15-20% of PAH patients have heritable PAH caused by genetic mutations.

Further, manufacturers undergo various initiatives to provide information and resources to healthcare practitioners, fueling the market growth. The PAH Initiative supported by United Therapeutics provides resources and information to assist healthcare providers in treating patients affected by PAH. In addition, the United States Pulmonary Hypertension Scientific Registry was established as the first US PAH patient registry to investigate genetic information, reproductive histories, and environmental exposure data in a patient population. Thus, the rising cases of PAH diagnosed each year and initiatives undertaken by manufacturers fuel the demand for pulmonary arterial hypertension drugs and other treatment methods, further bolstering the pulmonary arterial hypertension market growth in the US.

Canada holds the second-largest share of the pulmonary arterial hypertension market in North America. Canada has a high prevalence of pulmonary arterial hypertension. According to the PHA Canada, it is estimated that ~10,000 population in the country are affected by pulmonary hypertension (PH), but ~5,000 have been diagnosed with it. A limited number of treatments are approved in Canada to slow the progression of PH and alleviate symptoms. Over the last two decades, only 10 PH-specific medical treatments have been approved in Canada for treating PAH. However, the centers specializing in treating PAH in adults and children are located across the country. Additionally, a study (2022) published in European Respiratory Journal reported that the 1-, 3- and 5-year survival rates in the Canadian PAH cohort were 89.2%, 75.6%, and 56.0%, respectively. Thus, PAH patients in Canada are reported to have a high death rate in the long term.

The World Health Organization (WHO), US Food and Drug Administration (FDA), and National Organization for Rare Disorders (NORD) are among the primary and secondary sources referred to while preparing the report on the pulmonary arterial hypertension market.

TABLE OF CONTENTS

1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Pulmonary Arterial Hypertension Market - By Drugs
1.3.2 Global Pulmonary Arterial Hypertension Market - By Type
1.3.3 Global Pulmonary Arterial Hypertension Market - By Route of Administration
1.3.4 Global Pulmonary Arterial Hypertension Market - By Distribution Channel
1.3.5 Global Pulmonary Arterial Hypertension Market - By Geography
2. Pulmonary Arterial Hypertension Market - Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Pulmonary Arterial Hypertension Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.2.2 Europe PEST Analysis
4.2.3 Asia Pacific PEST Analysis
4.2.4 Middle East and Africa PEST Analysis
4.2.5 South and Central America PEST Analysis
4.3 Experts Opinion
5. Pulmonary Arterial Hypertension Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Incidence of Pulmonary Arterial Hypertension
5.1.2 Rising Approvals of Pulmonary Arterial Hypertension Drugs
5.2 Market Restraints
5.2.1 Side Effects of Drugs Used for Treatment of Pulmonary Arterial Hypertension
5.3 Market Opportunities
5.3.1 Availability of Generics at Affordable Costs Due to Growing Patent Expiration
5.3.2 Drugs Patents Expiration Data
5.4 Future Trend
5.4.1 Rising Clinical Trials for Drugs Development to Treat Pulmonary Arterial Hypertension
5.5 Impact analysis
6. Pulmonary Arterial Hypertension Market - Global Analysis
6.1 Global Pulmonary Arterial Hypertension Market Revenue Forecast and Analysis
6.2 Global Pulmonary Arterial Hypertension Market, By Geography - Forecast and Analysis
6.3 Market Positioning of Key Players
7. Global Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Drugs
7.1 Overview
7.2 Pulmonary Arterial Hypertension Market Revenue Share, by Drugs 2021 & 2028 (%)
7.3 Endothelin Receptor Antagonists (ERAs)
7.3.1 Overview
7.3.2 Endothelin Receptor Antagonists (ERAs): Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
7.4 Prostacyclin and Prostacyclin Analogs
7.4.1 Overview
7.4.2 Prostacyclin and Prostacyclin Analogs: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
7.5 SGC Stimulators
7.5.1 Overview
7.5.2 SGC Stimulators: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
7.6 Pde-5 Dipsticks
7.6.1 Overview
7.6.2 Pde-5 Dipsticks: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
8. Global Pulmonary Arterial Hypertension Market Analysis and Forecasts to 2028 - by Type
8.1 Overview
8.2 Global Pulmonary Arterial Hypertension Market, by Type 2021 & 2028 (%)
8.3 Branded
8.3.1 Overview
8.3.2 Branded: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
8.4 Generics
8.4.1 Overview
8.4.2 Generics: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
9. Global Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Route of Administration
9.1 Overview
9.2 Pulmonary Arterial Hypertension Market Revenue Share, by Route of Administration 2021 & 2028 (%)
9.3 Oral
9.3.1 Overview
9.3.2 Oral: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
9.4 Intravenous/ Subcutaneous
9.4.1 Overview
9.4.2 Intravenous/ Subcutaneous: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
9.5 Inhalational
9.5.1 Overview
9.5.2 Inhalational: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
10. Global Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Distribution Channel
10.1 Overview
10.2 Pulmonary Arterial Hypertension Market Revenue Share, by Distribution Channel 2021 & 2028 (%)
10.3 Hospital Pharmacies and Clinics
10.3.1 Overview
10.3.2 Hospital Pharmacies and Clinics: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
10.4 Online Pharmacies
10.4.1 Overview
10.4.2 Online Pharmacies: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
10.5 Retail Pharmacies
10.5.1 Overview
10.5.2 Retail Pharmacies: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11. Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - Geographic Analysis
11.1 North America: Pulmonary Arterial Hypertension Market
11.1.1 Overview
11.1.2 North America: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.1.3 North America: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.1.4 North America: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.1.5 North America: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.1.6 North America: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.1.6.1 US: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.1.6.1.1 Overview
11.1.6.1.2 US: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.1.6.1.3 US: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.1.6.1.4 US: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.1.6.1.5 US: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.1.6.1.6 US: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.1.6.2 Canada: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.1.6.2.1 Overview
11.1.6.2.2 Canada: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.1.6.2.3 Canada: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.1.6.2.4 Canada: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.1.6.2.5 Canada: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.1.6.2.6 Canada: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.1.6.3 Mexico: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.1.6.3.1 Overview
11.1.6.3.2 Mexico: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.1.6.3.3 Mexico: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.1.6.3.4 Mexico: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.1.6.3.5 Mexico: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.1.6.3.6 Mexico: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.2 Europe: Pulmonary Arterial Hypertension Market
11.2.1 Overview
11.2.2 Europe: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.2.3 Europe: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.2.4 Europe: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.2.5 Europe: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.2.6 Europe: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.2.7 Europe: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
11.2.7.1 UK: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.2.7.1.1 Overview
11.2.7.1.2 UK: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.2.7.1.3 UK: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.2.7.1.4 UK: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.2.7.1.5 UK: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.2.7.1.6 UK: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.2.7.2 Germany: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.2.7.2.1 Overview
11.2.7.2.2 Germany: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.2.7.2.3 Germany: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.2.7.2.4 Germany: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.2.7.2.5 Germany: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.2.7.2.6 Germany: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.2.7.3 France: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.2.7.3.1 Overview
11.2.7.3.2 France: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.2.7.3.3 France: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.2.7.3.4 France: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.2.7.3.5 France: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.2.7.3.6 France: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.2.7.4 Italy: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.2.7.4.1 Overview
11.2.7.4.2 Italy: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.2.7.4.3 Italy: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.2.7.4.4 Italy: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.2.7.4.5 Italy: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.2.7.4.6 Italy: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.2.7.5 Spain: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.2.7.5.1 Overview
11.2.7.5.2 Spain: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.2.7.5.3 Spain: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.2.7.5.4 Spain: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.2.7.5.5 Spain: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.2.7.5.6 Spain: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.2.7.6 Rest of Europe: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.2.7.6.1 Overview
11.2.7.6.2 Rest of Europe: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.2.7.6.3 Rest of Europe: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.2.7.6.4 Rest of Europe: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.2.7.6.5 Rest of Europe: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.2.7.6.6 Rest of Europe: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.3 Asia Pacific: Pulmonary Arterial Hypertension Market
11.3.1 Overview
11.3.2 Asia Pacific: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.3.3 Asia Pacific: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.3.4 Asia Pacific: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.3.5 Asia Pacific: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.3.6 Asia Pacific: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.3.7 Asia Pacific: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
11.3.7.1 China: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.3.7.1.1 Overview
11.3.7.1.2 China: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.3.7.1.3 China: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.3.7.1.4 China: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.3.7.1.5 China Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.3.7.1.6 China Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.3.7.2 Japan: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.3.7.2.1 Overview
11.3.7.2.2 Japan: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.3.7.2.3 Japan: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.3.7.2.4 Japan: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.3.7.2.5 Japan: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.3.7.2.6 Japan: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.3.7.3 India: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.3.7.3.1 Overview
11.3.7.3.2 India: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.3.7.3.3 India: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.3.7.3.4 India: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.3.7.3.5 India: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.3.7.3.6 India: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.3.7.4 South Korea: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.3.7.4.1 Overview
11.3.7.4.2 South Korea: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.3.7.4.3 South Korea: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.3.7.4.4 South Korea: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.3.7.4.5 South Korea: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.3.7.4.6 South Korea: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.3.7.5 Australia: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.3.7.5.1 Overview
11.3.7.5.2 Australia: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.3.7.5.3 Australia: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.3.7.5.4 Australia: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.3.7.5.5 Australia: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.3.7.5.6 Australia: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.3.7.6 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.3.7.6.1 Overview
11.3.7.6.2 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.3.7.6.3 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.3.7.6.4 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.3.7.6.5 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.3.7.6.6 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.4 South and Central America Pulmonary Arterial Hypertension Market
11.4.1 Overview
11.4.2 South and Central America: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.4.3 South and Central America: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.4.4 South and Central America: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.4.5 South and Central America: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.4.6 South and Central America: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.4.7 South and Central America: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
11.4.7.1 Brazil: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.4.7.1.1 Overview
11.4.7.1.2 Brazil: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.4.7.1.3 Brazil: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.4.7.1.4 Brazil: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.4.7.1.5 Brazil: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.4.7.1.6 Brazil: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.4.7.2 Argentina: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.4.7.2.1 Overview
11.4.7.2.2 Argentina: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.4.7.2.3 Argentina: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.4.7.2.4 Argentina: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.4.7.2.5 Argentina: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.4.7.2.6 Argentina: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.4.7.3 Rest of South and Central America: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.4.7.3.1 Overview
11.4.7.3.2 Rest of South and Central America: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.4.7.3.3 Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.4.7.3.4 Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.4.7.3.5 Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.4.7.3.6 Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.5 Middle East & Africa Pulmonary Arterial Hypertension Market
11.5.1 Overview
11.5.2 Middle East & Africa: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.5.3 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.5.4 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.5.5 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.5.6 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.5.7 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
11.5.7.1 UAE: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
11.5.7.1.1 Overview
11.5.7.1.2 UAE: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.5.7.1.3 UAE: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.5.7.1.4 UAE: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.5.7.1.5 UAE: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.5.7.1.6 UAE: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.5.7.2 Saudi Arabia: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
11.5.7.2.1 Overview
11.5.7.2.2 Saudi Arabia: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.5.7.2.3 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.5.7.2.4 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.5.7.2.5 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.5.7.2.6 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.5.7.3 South Africa: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
11.5.7.3.1 Overview
11.5.7.3.2 South Africa: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.5.7.3.3 South Africa: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.5.7.3.4 South Africa: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.5.7.3.5 South Africa: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.5.7.3.6 South Africa: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.5.7.4 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
11.5.7.4.1 Overview
11.5.7.4.2 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.5.7.4.3 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.5.7.4.4 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.5.7.4.5 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.5.7.4.6 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
12. Impact Of COVID-19 Pandemic on Pulmonary Arterial Hypertension Market
12.1 North America: Impact Assessment of COVID-19 Pandemic
12.2 Europe: Impact Assessment of COVID-19 Pandemic
12.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic
12.4 South & Central America: Impact Assessment of COVID-19 Pandemic
12.5 Middle East & Africa: Impact Assessment of COVID-19 Pandemic
13. Pulmonary Arterial Hypertension Market - Industry Landscape
13.1 Overview
13.2 Growth Strategies in the Pulmonary Arterial Hypertension Market (%)
13.3 Organic Developments
13.3.1 Overview
13.4 Inorganic Developments
13.4.1 Overview
14. Company Profiles
14.1 Johnson & Johnson
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Gilead Sciences Inc
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 United Therapeutics Corp
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Bayer AG
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Aerami Therapeutics Holdings Inc
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Novartis AG
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 GSK Plc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Teva Pharmaceutical Industries Ltd
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 Lupin Ltd
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 Pfizer Inc
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. Appendix
15.1 About The Insight Partners
15.2 Glossary of Terms

LIST OF TABLES

Table 1. Drugs Patents Expiration Data
Table 2. North America Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 3. North America Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 4. North America Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 5. North America Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 6. US Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 7. US Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 8. US Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 9. US Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 10. Canada Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 11. Canada Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 12. Canada Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 13. Canada Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 14. Mexico Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 15. Mexico Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 16. Mexico Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 17. Mexico Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 18. Europe Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 19. Europe Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 20. Europe Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 21. Europe Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 22. UK Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 23. UK Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 24. UK Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 25. UK Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 26. Germany Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 27. Germany Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 28. Germany Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 29. Germany Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 30. France Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 31. France Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 32. France Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 33. France Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 34. Italy Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 35. Italy Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 36. Italy Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 37. Italy Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 38. Spain Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 39. Spain Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 40. Spain Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 41. Spain Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 42. Rest of Europe Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 43. Rest of Europe Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 44. Rest of Europe Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 45. Rest of Europe Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 46. Asia Pacific Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 47. Asia Pacific Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 48. Asia Pacific Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 49. Asia Pacific Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 50. China Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 51. China Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 52. China Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 53. China Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 54. Japan Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 55. Japan Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 56. Japan Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 57. Japan Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 58. India Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 59. India Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 60. India Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 61. India Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 62. South Korea Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 63. South Korea Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 64. South Korea Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 65. South Korea Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 66. Australia Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 67. Australia Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 68. Australia Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 69. Australia Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 70. Rest of Asia Pacific Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 71. Rest of Asia Pacific Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 72. Rest of Asia Pacific Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 73. Rest of Asia Pacific Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 74. South and Central America: Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 75. South and Central America: Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 76. South and Central America: Pulmonary Arterial Hypertension Market, by Route of Administration- Revenue and Forecast to 2028 (US$ Million)
Table 77. South and Central America: Pulmonary Arterial Hypertension Market, by Distribution Channel- Revenue and Forecast to 2028 (US$ Million)
Table 78. Brazil: Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 79. Brazil: Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 80. Brazil: Pulmonary Arterial Hypertension Market, by Route of Administration- Revenue and Forecast to 2028 (US$ Million)
Table 81. Brazil: Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 82. Argentina: Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 83. Argentina: Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 84. Argentina: Pulmonary Arterial Hypertension Market, by Route of Administration- Revenue and Forecast to 2028 (US$ Million)
Table 85. Argentina: Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 86. Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 87. Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 88. Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Route of Administration- Revenue and Forecast to 2028 (US$ Million)
Table 89. Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 90. Middle East & Africa Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 91. Middle East & Africa Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 92. Middle East & Africa Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 93. Middle East & Africa Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 94. UAE Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 95. UAE Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 96. UAE Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 97. UAE Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 98. Saudi Arabia Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 99. Saudi Arabia Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 100. Saudi Arabia Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 101. Saudi Arabia Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 102. South Africa Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 103. South Africa Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 104. South Africa Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 105. South Africa Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 106. Rest of the Middle East and Africa Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 107. Rest of the Middle East and Africa Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 108. Rest of the Middle East and Africa Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 109. Rest of the Middle East and Africa Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 110. Organic Developments in the Pulmonary Arterial Hypertension Market
Table 111. Inorganic Developments in the Pulmonary Arterial Hypertension Market
Table 112. Glossary of Terms

LIST OF FIGURES

Figure 1. Pulmonary Arterial Hypertension Market Segmentation
Figure 2. Pulmonary Arterial Hypertension Market - By Geography
Figure 3. Pulmonary Arterial Hypertension Market Overview
Figure 4. Prostacyclin and Prostacyclin Analogs Segment Held Largest Share by Drugs of Pulmonary Arterial Hypertension Market
Figure 5. Asia Pacific to Show Significant Growth During Forecast Period
Figure 6. Pulmonary Arterial Hypertension Market, by Geography (US$ Million)
Figure 7. Global Pulmonary Arterial Hypertension Market - Leading Country Markets (US$ Million)
Figure 8. Global Pulmonary Arterial Hypertension Market, Industry Landscape
Figure 9. North America: PEST Analysis
Figure 10. Europe: PEST Analysis
Figure 11. Asia Pacific: PEST Analysis
Figure 12. Middle East and Africa: PEST Analysis
Figure 13. South and Central America: PEST Analysis
Figure 14. Experts Opinion
Figure 15. Pulmonary Arterial Hypertension Market Impact Analysis of Drivers and Restraint
Figure 16. Global Pulmonary Arterial Hypertension Market- Revenue Forecast and Analysis - 2020 - 2028
Figure 17. Global Pulmonary Arterial Hypertension Market - By Geography Forecast and Analysis - 2022 - 2028
Figure 18. Market Positioning of Key Players in Pulmonary Arterial Hypertension Market
Figure 19. Pulmonary Arterial Hypertension Market Revenue Share, by Drugs 2021 & 2028 (%)
Figure 20. Endothelin Receptor Antagonists (ERAs): Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 21. Prostacyclin and Prostacyclin Analogs: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 22. SGC Stimulators: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 23. Pde-5 Dipsticks: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 24. Global Pulmonary Arterial Hypertension Market, by Type 2021 & 2028 (%)
Figure 25. Branded: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 26. Generics: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 27. Pulmonary Arterial Hypertension Market Revenue Share, by Route of Administration 2021 & 2028 (%)
Figure 28. Oral: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 29. Intravenous/ Subcutaneous: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 30. Inhalational: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 31. Pulmonary Arterial Hypertension Market Revenue Share, by Distribution Channel 2021 & 2028 (%)
Figure 32. Hospital Pharmacies and Clinics: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 33. Online Pharmacies: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 34. Retail Pharmacies: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 35. North America: Pulmonary Arterial Hypertension Market, by Key Country - Revenue (2021) (US$ Million)
Figure 36. North America Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 37. North America: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
Figure 38. US: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 39. Canada: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 40. Mexico: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 41. Europe: Pulmonary Arterial Hypertension Market, by Key Country - Revenue (2021) (US$ Million)
Figure 42. Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 43. Europe: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
Figure 44. Germany: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 45. Germany: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 46. France: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 47. Italy: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 48. Spain: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 49. Rest of Europe: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 50. Asia Pacific: Pulmonary Arterial Hypertension Market, by Key Country - Revenue (2021) (US$ Million)
Figure 51. Asia Pacific Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 52. China: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 53. Japan: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 54. India: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 55. South Korea: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 56. Australia: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 57. Rest of Asia Pacific: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 58. South and Central America: Pulmonary Arterial Hypertension Market, by Key Country - Revenue (2021) (US$ Million)
Figure 59. South and Central America Pulmonary Arterial Hypertension Market Revenue and Forecast to 2028 (US$ Million)
Figure 60. South and Central America: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
Figure 61. Brazil: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 62. Argentina: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 63. Rest of South and Central America: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 64. Middle East & Africa: Pulmonary Arterial Hypertension Market, by Key Country - Revenue (2021) (US$ Million)
Figure 65. Middle East & Africa Pulmonary Arterial Hypertension Market Revenue and Forecast to 2028 (USD Million)
Figure 66. UAE: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 67. Saudi Arabia: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 68. South Africa: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 69. Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 70. Impact of COVID-19 Pandemic in North America Country Markets
Figure 71. Impact of COVID-19 Pandemic in European Country Markets
Figure 72. Impact of COVID-19 Pandemic on Asia Pacific Country Markets
Figure 73. Impact of COVID-19 Pandemic in South and Central American Countries
Figure 74. Impact of COVID-19 Pandemic on Middle East and Africa Country Markets
Figure 75. Growth Strategies in the Pulmonary Arterial Hypertension Market (%)

  • Not Sure / Need Reassuring
    • Confirm Content

      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages

      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives

      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices

      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts

      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies

      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses

      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License

      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats

      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery

      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges

      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card

      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer

      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security

      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security

      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE
  • $4550.00 $3185.00
  • $6550.00 $4585.00
  • $8550.00 $5985.00
  • ADD TO BASKET
  • BUY NOW